Stephens Investment Management Group LLC Acquires 427,991 Shares of Amicus Therapeutics, Inc. $FOLD

Stephens Investment Management Group LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 51.4% in the 3rd quarter, Holdings Channel reports. The fund owned 1,260,634 shares of the biopharmaceutical company’s stock after purchasing an additional 427,991 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Amicus Therapeutics were worth $9,934,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of FOLD. CANADA LIFE ASSURANCE Co raised its stake in Amicus Therapeutics by 2.8% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 2,263 shares during the last quarter. Osaic Holdings Inc. grew its position in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the period. Police & Firemen s Retirement System of New Jersey raised its position in shares of Amicus Therapeutics by 5.9% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 66,238 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 3,688 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Amicus Therapeutics during the first quarter valued at about $30,000.

Insider Activity

In related news, CEO Bradley L. Campbell sold 77,926 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $10.86, for a total transaction of $846,276.36. Following the transaction, the chief executive officer owned 1,129,782 shares in the company, valued at $12,269,432.52. This represents a 6.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Michael Clark sold 25,643 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93. Following the sale, the insider directly owned 322,618 shares in the company, valued at $3,068,097.18. This trade represents a 7.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 345,450 shares of company stock valued at $3,657,000 in the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FOLD. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Cantor Fitzgerald cut Amicus Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $21.00 to $14.50 in a research report on Friday, December 19th. Guggenheim cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $15.67.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $14.33 on Friday. The business has a 50 day simple moving average of $11.73 and a 200 day simple moving average of $9.01. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The company has a market capitalization of $4.42 billion, a PE ratio of -358.16 and a beta of 0.42. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 earnings per share. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.